Philippe Drouet, Biotheryx CEO
Incyte links arms with tiny Biotheryx for protein degrader deal, targeting cancer
Incyte is jumping in on Biotheryx’s platform, looking for potential protein degraders for a new, undisclosed oncology target.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
